Clinical manifestations of β-thalassaemia and sickle cell anaemia (SCA) are extremely variable, ranging from nearly asymptomatic to severe and transfusion-dependant stage. The human β-globin gene cluster located on chromosome 11 has embryonic, foetal and adult globin genes, expressed sequentially during the various stages of development. The switch from human foetal (γ) to adult (β) globin gene expression has been of particular interest because of its clinical importance. Reactivation of foetal haemoglobin (HbF) or delay of switch in adult stage has been reported to ameliorate the clinical severity in β-haemoglobin disorders like β-thalassaemia and SCA[@ref1].

Genome wide association studies (GWAS) have identified genetic variants that fall outside of the β-haemoglobin gene. A new HbF associated locus on chromosome 2, located within the gene *BCL11A* (B-cell lymphoma/leukemia 11A) was identified by these studies[@ref1][@ref2][@ref3][@ref4][@ref5]. The *BCL11A* gene encoding a zinc finger transcription factor was shown to be downregulated in adult human erythroid precursor resulting in induction of HbF[@ref2].

In a previous GWAS in a Sardinian population the minor allele of single nucleotide polymorphism (SNP) rs11886868 in the *BCL11A* gene was found to associate significantly with an increase in the production of HbF[@ref6]. However, an association could not be established between this SNP and increased HbF levels in some other ethnic groups[@ref5][@ref6] indicating a discrepancy in different populations. Therefore, this study was carried out to investigate the frequency of SNP rs11886868 (T/C) in the *BCL11A* gene with severity of the β-thalassaemia major and SCA in patient population attending a tertiary care hospital in Telangana, India.

Material & Methods {#sec1-2}
==================

The study was carried out at the Institute of Genetics and Hospital for Genetic Diseases, Hyderabad, Telangana, India. Of the 6500 individuals who visited this institute during January 2005 to December 2012, 420 patients confirmed to be affected with β-thalassaemia major and 200 with SCA were included in the study. Patients suffering from any other kind of haematological disorders were excluded from the study. Individuals who were carriers of the disease or had other structural variants of Hb were also excluded from the study.

Information on clinical characteristics of the patients was collected by using a structured questionnaire. Institutional Ethics Committee clearance was taken for the study. Blood samples (3 ml) were collected from the patients in EDTA vacutainers after obtaining written informed consent. Patients (n=620) confirmed to be affected by β-thalassaemia (n=420) or SCA (n=200) by high performance liquid chromatography (HPLC) and genomic DNA analysis were included in the study. All patients recruited in the study were transfusion dependent. HPLC technique was used with the β-Thalassaemia Short Program of Variant Bio-Rad (Bio-Rad, USA) (Figs [1](#F1){ref-type="fig"}, [2](#F2){ref-type="fig"}). The complete blood picture of all the patients was analysed before analysing the samples by HPLC.

![**(a)**. HPLC chromatogram of a normal individual (A2- 2.1%; HbF-0.0% both A2 and HbF are in the normal range), **(b)** HPLC chromatogram of a β-thalassaemia carrier (A2-4.3%; HbF-0.4% A2 is high), **(c)** HPLC chromatogram of a sickle cell carrier (HbS- 8.8%; HbF-1.7% HbS in high range).](IJMR-143-449-g001){#F1}

![**(a)**. HPLC chromatogram of a β-thalassaemia major (the chromatorgram is of a transfused beta thalassaemia major (A2-7.5%; HbF-3.7% both A2 and HbF are high), **(b)** HPLC chromatogram of a sickle cell anaemia (HbS-39.4%; HbF-10.6% both HbS and HbF are in high range), **(c)** HPLC chromatogram of a E-disease (A2-48.3%; hbF-3.9% A2 is too high HbF also high).](IJMR-143-449-g002){#F2}

*Clinical severity*: The patients who had two β-thalassaemia alleles and two HbS alleles (based on mutation analysis) were categorized into mild, moderate, and severe groups by a systematic scoring system proposed by Sripichai *et al*[@ref7]. Based on clinical observations alone, 310 patients were found to be thalassaemia intermedia (Hb level of at least 7g/dl at the time of diagnosis). Parameters that showed a correlation with disease severity (at r \> 0.3) were included in the multiple logistic regression analysis. These were haemoglobin level, age of onset, age at which patients received their first blood transfusion, age at thalassaemia presentation, the degree of growth retardation, and splenectomy as reported previously[@ref8][@ref9]. The scoring system consisting of these six clinical criteria scored 0, 0.5, 1, or 2 according to clinical presentation. Patients whose severity score was \<3.5, 3.5-7.5, and \>7.5 were considered as mild, moderate, and severe cases, respectively.

*Molecular studies*: Genomic DNA was extracted from the whole blood samples using the phenol-chloroform method[@ref10]. Amplification refractory mutation system (ARMS)-PCR and reverse dot blot (RDB) hybridization were used to screen the specific mutation in patients with β-thalassaemia and HbS in SCA as reported previously[@ref11][@ref12]. Single nucleotide polymorphism of rs11886868 in the *BCL11A* gene (T→C) was detected by PCR-RFLP technique. A 548bp fragment was amplified using the primers 5'-TTTGGTGCTACCCTGAAAGAC-3' and 5'-ACTCAACAGTAGCAGAATGAAAGAG-3 (<http://simgene.com/Primer3>). The 548-bp product was digested with MboII restriction enzyme (<http://tools.neb.com/NEBcutter2/>) by incubating at 37°C for five min, followed by separation of fragments on three per cent agarose gel. The T allele lacks the MboII restriction site, while it is present in the C allele. The C allele was detected as two fragments of 470 bp and 70 bp.

*Statistical analysis*: Association between the genotype and severity was examined by odds ratio with 95% confidence interval (CI) and Chi-squared analysis using Open Epi software (Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, USA). Allelic frequencies were calculated according to the number of alleles observed and the total number of alleles examined. The association of different genotypes with HbF percentage was evaluated by One-way ANOVA.

Results {#sec1-3}
=======

A total of 6500 individuals were tested using HPLC, ARMS-PCR (Figs [1](#F1){ref-type="fig"}--[3](#F3){ref-type="fig"}) and RDB techniques for one of the heterogeneous group of congenital anaemia which includes β-thalassaemia, haemoglobin variants (D-thalassaemia, E-thalassaemia and SCA) and hereditary persistance of foetal haemoglobin (HPFH). The break-up of the analysed cases and the spectrum of mutations was in conformity with our previous publications[@ref8][@ref9]. The patients (420 β-thalassaemia, 200 SCA) were divided into subgroups (mild, moderate, and severe) based on the severity of the disease. The clinical data and biochemical characteristics of β-thalassaemia and SCA patients are given in Tables [I](#T1){ref-type="table"} and [II](#T2){ref-type="table"}. There were 131 mild, 179 moderate and 110 severe β-thalassaemia patients. The SCA patients in mild, moderate and severe groups were 117, 63 and 20, respectively. Genotypic and allele frequencies of *BCL11A* (T/C) gene polymorphism in both the patient group are given in [Table III](#T3){ref-type="table"}. There was a significant difference in the mean HbF levels between the three genotypes in different severity groups (*P*\<0.001) in both β-thalassaemia and SCA patients. HbF levels were found to be higher in individuals with CC genotype followed by TC and TT genotype in β-thalassaemia major as well as in SCA patients ([Table III](#T3){ref-type="table"}). There was a significant difference in the genotypic distribution and allele frequency between mild and moderate, mild and severe groups in β-thalassaemia major as well as in SCA patients. With regards to *BCL11A* gene polymorphism, there was a significant difference in the high and low percentage HbF levels between the three genotypes in both SCA and β-thalassaemia patients (Tables [IV](#T4){ref-type="table"}, [V](#T5){ref-type="table"}).

![Gel pictures of *BCL11A* gene polymorphism. **(a)** Lanes 1, 2, 3, 5, 6, 7 and 8 represent the amplified product of *BCL11A* gene and lane 4 represents 100 bp ladder. **(b)** restriction fragment length polymorphism (RFLP) of *BCL11A* gene polymorphism. Lanes 1, 2 and 5 represent heterozygous condition 6, and 7 represents homozygous condition. Lane 3 represents homozygous mutant.](IJMR-143-449-g003){#F3}
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Clinical and biochemical characteristics of β-thalassaemia patients according to the severity of disease
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Clinical and biochemical characteristics of sickle cell anaemia (SCA) patients according to the severity of disease
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Distribution of genotype and allele frequencies of *BCL11A* gene polymorphism and of HbF levels in β-thalassaemia and SCA patients

![](IJMR-143-449-g006)

###### 

*BCL11A* gene polymorphism and percentage of HbF in β-thalassaemia patients

![](IJMR-143-449-g007)

###### 

*BCL11A* gene polymorphism and percentage of HbF in SCD patients
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Discussion {#sec1-4}
==========

Modifying factors that reduce the imbalance of α- vs. Non α-haemoglobin chains are the determinants of clinical severity of β-thalassaemia as well as SCA. The reduced globin chain imbalance allows selective survival of the erythroid precursors and thereby reduces the unproductive erythropoiesis[@ref6][@ref13].

It has been shown that the variants in *BCL11A*, *HBS1L-MYB* and *HBB* loci are associated with HbF levels and ameliorate the severity in β-thalassaemia as well as SCA[@ref14][@ref15]. *BCL11A* has been described as a major suppressor of HbF expression. Several SNPs located in *BCL11A* gene and linked to HbF levels and thus the severity of β-thalassaemia and SCA have been described[@ref2][@ref16]. The direct binding of this transcription factor on to several locations in the β-globin cluster, especially to a region located at 5'to the δ-globin gene has also been demonstrated[@ref4]. In a recent study it was found that the loss of this region was associated with an increase of 2.7g/dl of HbF. This would be sufficient to compensate the lack of Hb in β-thalassaemia major patients[@ref17].

The minor allele 'C' of SNP rs11886868 in the *BCL11A* gene has been shown to be a major modifier of HbF levels, than *HBS1L-MYB* locus or the co-inheritance of α-thalassaemia[@ref15]. However, in Europeans *HBS1L-MYB* locus has been reported to have a stronger effect than *BCL11A*[@ref2]. The different amount of variants explained by each marker reflects the heterogeneity of the allele frequencies among different ethnic groups. A significant association of CC genotype and C allele was observed with the milder disease phenotype in β-thalassaemia as well as SCA in the present study. The frequency of CC variant genotype was found to be 40 per cent in our study population. However, the frequency of the CC genotype has been found to be 28.8 per cent in an Iranian population[@ref18]. Galanello *et al*[@ref15] have reported the frequency of CC genotype to be 61.2 per cent in Sardinians. The difference in the frequency of variant genotype might be on account of ethnic differences[@ref15]. This study confirms that increased γ-globin expression associated with the *BCL11A* (T/C) polymorphism ameliorates the clinical severity in these haemoglobinopathies in the study population. The patients were also assessed based on the age at diagnosis; 70 per cent of the CC bearing individuals were diagnosed after one year of age, while 30 per cent were diagnosed at less than one year of age in β-thalassaemia, whereas in the SCA 76 per cent of CC bearing individuals were diagnosed after one year while 26 per cent were diagnosed at less than one year of age.

The role of *BCL11A* as a regulator of γ-globin gene silencing has also been demonstrated experimentally by increased production of HbF in developing adult erythroblasts after small hairpin RNA (sh-RNA) mediated knocked down[@ref19]. *BCL11A* mediated silencing is orchestrated through cooperation with a high mobility group transcription factor SOX6, since *BCL11A* and *SOX6* are co-expressed and interact physically[@ref16][@ref19]. The data from genetic and functional studies support a key role for *BCL11A* in silencing of γ-globin genes during the developmental switching as well as its potential role in reactivation of HbF in adult erythroblasts.

In conclusion, the present study suggests that the HbF associated SNPs which increase the production of foetal Hb over the lifetime of a patient may be considered as an innate therapy for various haemoglobinopathies. Screening of *BCL11A* gene variants may eventually help to predict the severity of disease in newborn and will revolutionize the diagnosis, treatment and prevention.

The authors acknowledge the Department of Biotechnology (DBT), New Delhi, for financial support.

***Conflicts of Interest:*** None.

[^1]: *Present address*: Centre for Human Genetics & Molecular Medicine, Central University of Punjab, Bathinda, Punjab, India e-mail: <anjanadurani@yahoo.co.in>
